Business
Sanara MedTech Inc. and Biomimetic Innovations Provide Update on OsStic™
Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic’s granted patent in 2025 FORT WORTH, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, together with Biomimetic Innovations Ltd (“BMI”), today
About this update from Sanara Medtech Inc.
[{"type":"image","alt":"Sanara MedTech Inc.","displaySize":"","headline":null,"caption":"Sanara MedTech Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/3143d8c56f18cb5802cdd7512b027911"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ep49t7MgFH9O.p4QWc4Ouw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3143d8c56f18cb5802cdd7512b027911","width":300,"height":101}},"lazy":false},{"type":"text","content":"Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic’s granted patent in 2025","length":123,"tagName":"p"},{"type":"text","content":"FORT WORTH, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, together with Biomimetic Innovations Ltd (“BMI”), today provided an update on progress related to their strategic alliance. In addition, Sanara reaffirmed its plans to introduce OsStic™ Synthetic Injectable Structural Bio-Adhesive (“OsStic”) to the U.S. commercial market in the first quarter of 2027, following anticipated clearance by the U.S. Food and Drug Administration (“FDA”), to support reduction and provisional fixation treatment of the more than 100,000(1) peri-articular fractures occurring annually nationwide.","length":843,"tagName":"p"},{"type":"text","content":"The FDA granted OsStic Breakthrough Device Designation in December 2023, recognizing its potential to provide more effective treatment for life-threatening or irreversibly debilitating conditions. If cleared for the target indication, we expect that OsStic will be the first bone bioadhesive available in the U.S. that utilizes phosphoserine, alpha-tricalcium phosphate (α-TCP), and calcium silicate as key ingredients to support bone healing and enhance structural and mechanical stability. OsStic is fast-setting in bone tissue, injectable, moldable, and remodels into bone—addressing critical limitations of current provisional fixation techniques. Preclinical mechanical testing demonstrates that OsStic provides forty times stronger bonding than traditional...